Amgen sees no 'significant delays' from pandemic to novel KRAS cancer drug

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

In what may be a relief for some investors, its big, highly anticipated KRAS drug AMG 510 is already fully enrolled, and the company doesn’t see any “significant delays” for results here. (Though that line doesn’t rule out any smaller delays.)